FARN Faron Pharmaceuticals Oy

TIDMFARN

Faron Pharmaceuticals Oy

06 September 2023

Faron Pharmaceuticals Ltd. to Present at the H.C. Wainwright 25th Annual Global Investment Conference

TURKU, Finland / BOSTON, Massachusetts - September 6, 2023 - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that Dr Markku Jalkanen, PhD, CEO will present at the H.C. Wainwright Annual Global Investment Conference in New York City on September 12, 2023. In addition to the presentation, company management will be available for one-on-one meetings with investors.

H.C. Wainwright Global Investment Conference

Date: Tuesday, September 12, 2023

Time: 10:30 a.m. ET

Location: Room Holmes I, 4(th) floor

Format: Company Presentation

For more information please contact:

Investor Contact

LifeSci Advisors

Daniel Ferry

Managing Director

daniel@lifesciadvisors.com

+1 (617) 430-7576

Media Contact

Faron Pharmaceuticals

Jennifer C. Smith-Parker

Head of Communications

Jennifer.Smith-Parker@faron.com

About Faron Pharmaceuticals Ltd.

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through targeting myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com .

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRANKPBDCBKDDCK

(END) Dow Jones Newswires

September 06, 2023 02:00 ET (06:00 GMT)

Faron Pharmaceuticals Oy (LSE:FARN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024

Faron Pharmaceuticals Oy (LSE:FARN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024